{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:44:13Z","timestamp":1792827853052,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CeleCor Therapeutics","award":["CeleCor Therapeutics"],"award-info":[{"award-number":["CeleCor Therapeutics"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Understanding the pharmacodynamic effects of platelet inhibitors is standard for developing more effective antithrombotic therapies. An example is the antithrombotic treatment of acute coronary syndrome (ACS), in particular ST-elevated myocardial infarction (STEMI) patients who are in need for rapid acting strong antithrombotic therapy despite the use of aspirin and oral P2Y12-inhibitors. In this study, we evaluated two injectable platelet inhibitors under clinical development (the P2Y12 antagonist selatogrel and the GPIIb-IIIa antagonist zalunfiban) that may be amenable to pre-hospital treatment of STEMI patients. Platelet reactivity was assessed at inhibitor concentrations that represent clinically relevant levels of platelet inhibition (IC20-50%, 1\/2Cmax, and Cmax). Light transmission aggregometry (LTA), was used to evaluate the initial rate of aggregation (primary slope, PS) and maximal aggregation (MA). Both adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP) were used as agonists. Zalunfiban demonstrated similar inhibition of platelet aggregation when blood was collected in PPACK or TSC, whereas selatogrel demonstrated greater inhibition in PPACK. In this study, using PPACK anticoagulant, selatogrel and zalunfiban affected PS in response to ADP equivalently at all drug concentrations tested. In contrast, zalunfiban had significantly greater potency at its Cmax concentration compared to selatogrel using TRAP as agonist. Upon evaluation of MA responses at lower doses, selatogrel had greater inhibition of MA in response to ADP than zalunfiban; however, at concentrations that represent Cmax, the drugs were equivalent. Zalunfiban also had greater inhibition of MA in response to TRAP at the Cmax dose. These data suggest that zalunfiban may provide greater protection in reducing thrombus formation than selatogrel, especially since thrombin is an early, key primary agonist in the pathophysiology of thrombotic events.<\/jats:p>","DOI":"10.1007\/s11239-023-02867-x","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T17:01:59Z","timestamp":1691686919000},"page":"499-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation"],"prefix":"10.1007","volume":"56","author":[{"given":"Benjamin J.","family":"Curry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.F. Sem","family":"Rikken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W.J.","family":"van \u2018t Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-7775","authenticated-orcid":false,"given":"Lisa K.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"8607","key":"2867_CR1","first-page":"349","volume":"2","author":"Randomized Trial of Intravenous Streptokinase","year":"1988","unstructured":"Randomized Trial of Intravenous Streptokinase (1988) Randomized Trial of Intravenous Streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2(8607):349\u2013360","journal-title":"Lancet"},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capodanno","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (2018) ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 72:2915\u20132931 (23 Pt A). https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","journal-title":"J Am Coll Cardiol"},{"key":"2867_CR3","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, TRITON-TIMI-38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015, 2007. https:\/\/doi.org\/10.1056\/NEJMoa0706482","DOI":"10.1056\/NEJMoa0706482"},{"issue":"11","key":"2867_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon C, Emanuelsson H, Held C, PLATO Investigators et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"2867_CR5","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404\u20131413. https:\/\/doi.org\/10.1056\/NEJMoa1200933","journal-title":"N Engl J Med"},{"key":"2867_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1109719","journal-title":"N Engl J Med"},{"key":"2867_CR7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","volume":"122","author":"PG Steg","year":"2010","unstructured":"Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L, PLATO Study Group (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 122:2131\u20132141. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.927582","journal-title":"Circulation"},{"issue":"6","key":"2867_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","volume":"5","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5(6):797\u2013804. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.112.972323","journal-title":"Circ Cardiovasc Interv"},{"issue":"15","key":"2867_CR9","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 61(15):1601\u20131606. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.024","journal-title":"J Am Coll Cardiol"},{"key":"2867_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.thromres.2016.05.019","volume":"143","author":"N Khan","year":"2016","unstructured":"Khan N, Cox AR, Cotton JM (2016) Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: a systematic review. Thromb Res 143:141\u2013148. https:\/\/doi.org\/10.1016\/j.thromres.2016.05.019","journal-title":"Thromb Res"},{"issue":"19","key":"2867_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","volume":"58","author":"SS Brar","year":"2011","unstructured":"Brar SS, ten Berg J, Marcucci R et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. J Am Coll Cardiol 58(19):1945\u20131954. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.059","journal-title":"J Am Coll Cardiol"},{"key":"2867_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14779072.2016.1204912","volume":"14:9","author":"C Pappas","year":"2016","unstructured":"Pappas C, Lekakis J, Alexopoulos D (2016) Ticagrelor recommended over clopidogrel in STEMI patients. Expert Rev Cardiovasc Ther 14:9:983\u2013985. https:\/\/doi.org\/10.1080\/14779072.2016.1204912","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2867_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/rth2.12115","volume":"2","author":"T Gremmel","year":"2018","unstructured":"Gremmel T, Michelson AD, Frelinger ALIII, Bhatt DL (2018) Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2:439\u2013449. https:\/\/doi.org\/10.1002\/rth2.12115","journal-title":"Res Pract Thromb Haemost"},{"issue":"21","key":"2867_CR14","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","volume":"134","author":"Z Motovska","year":"2016","unstructured":"Motovska Z, Hlinomaz O, Miklik R, PRAGUE-18 Study Group et al (2016) Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: Multicenter randomized PRAGUE-18 study. Circulation 134(21):1603\u20131612. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024823","journal-title":"Circulation"},{"key":"2867_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/dme.14868","volume":"3","author":"PP Wadowski","year":"2022","unstructured":"Wadowski PP, Pultar J, Welkert C, Eichelberger B, Panzer B, Huber K, Lang IM, Koppensteiner R, Panzer S, Gremmel T (2022) Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Res Pract Thromb Haemost 3:383\u2013390. https:\/\/doi.org\/10.1111\/dme.14868","journal-title":"Res Pract Thromb Haemost"},{"issue":"18","key":"2867_CR16","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","volume":"56","author":"RF Storey","year":"2010","unstructured":"Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L (2010) Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary synfromes: the PLATO (PLATelet inhibition and patient outcomes) platelet substudy. J am Coll Cardiol 56(18):1456\u20131462. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.100","journal-title":"J am Coll Cardiol"},{"issue":"14","key":"2867_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"EPIC Investigators","year":"1994","unstructured":"Investigators EPIC (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330(14):956\u2013961. https:\/\/doi.org\/10.1056\/NEJM199404073301402","journal-title":"N Engl J Med"},{"issue":"25","key":"2867_CR18","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","volume":"344","author":"G Montalescot","year":"2001","unstructured":"Montalescot G, Barragan P, Wittenberg O, ADMIRAL Investigators et al (2001) Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344(25):1895\u20131903. https:\/\/doi.org\/10.1056\/NEJM200106213442503","journal-title":"N Engl J Med"},{"issue":"07","key":"2867_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJM199808133390704","volume":"339","author":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators","year":"1998","unstructured":"Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators (1998) Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339(07):436\u2013443. https:\/\/doi.org\/10.1056\/NEJM199808133390704","journal-title":"N Engl J Med"},{"issue":"21","key":"2867_CR20","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators","year":"1998","unstructured":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators (1998) Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 338(21):1488\u20131497. https:\/\/doi.org\/10.1056\/NEJM199805213382102","journal-title":"N Engl J Med"},{"issue":"22","key":"2867_CR21","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","volume":"55","author":"JM ten Berg","year":"2010","unstructured":"ten Berg JM, van\u2019t Hof AW, Dill T, -TIME 2 Study Group (2010) Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcomes. J Am Coll Cardiol 55(22):2446\u20132455. https:\/\/doi.org\/10.1016\/j.jacc.2009.11.091. On","journal-title":"J Am Coll Cardiol"},{"issue":"2 Suppl","key":"2867_CR22","doi-asserted-by":"publisher","first-page":"53S","DOI":"10.1378\/chest.127.2_suppl.53S","volume":"127","author":"RH Aster","year":"2005","unstructured":"Aster RH (2005) Immune thrombocytopenia caused by glycoprotein IIb\/IIIa inhibitors. Chest 127(2 Suppl):53S\u20139S. https:\/\/doi.org\/10.1378\/chest.127.2_suppl.53S","journal-title":"Chest"},{"issue":"10","key":"2867_CR23","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","volume":"34","author":"J Li","year":"2014","unstructured":"Li J, Vootukuri S, Shang Y, Negri A, Jiang J-K, Nedelman M, Diacovo TG, Filizola M, Thomas CJ, Coller BS (2014) RUC-4: a novel aIIbb3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 34(10):2321\u20132329. https:\/\/doi.org\/10.1161\/ATVBAHA.114.303724","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2867_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4244\/EIJ-D-21-00287","volume":"1","author":"WL Bor","year":"2021","unstructured":"Bor WL, Zheng KL, Tavenier AH, Gibson CM, Granger CB, Bentur O, Lobatto R, Postma S, Coller BS, van\u2019t Hof AWJ, ten Berg JM (2021) Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb\/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. EuroIntervention 1:17. https:\/\/doi.org\/10.4244\/EIJ-D-21-00287","journal-title":"EuroIntervention"},{"issue":"33","key":"2867_CR25","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","volume":"41","author":"RF Storey","year":"2020","unstructured":"Storey RF, Gurbel PA, Ten Berg J et al (2020) Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 41(33):3132\u20133140. https:\/\/doi.org\/10.1093\/eurheartj\/ehz807","journal-title":"Eur Heart J"},{"key":"2867_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40261-014-0236-8","volume":"34","author":"D Baldoni","year":"2014","unstructured":"Baldoni D, Bruderer S, Krause A, Gutierrez M, Gueret P, Astruc B, Dingermanse J (2014) A new reversible and potent P2Y12 receptor antagonist (ACT-246475) tolerability, pharmacokinetics, and pharmacodynamics in first-in-man trial. Clin Drug Investig 34:807\u2013818. https:\/\/doi.org\/10.1007\/s40261-014-0236-8","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2867_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/09537104.2020.1869711","volume":"33","author":"M Baumann","year":"2022","unstructured":"Baumann M, Lack B, Guillaumat I, Murphy MJ, Riederer MA (2022) The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration. Platelets 33(1):147\u2013156. https:\/\/doi.org\/10.1080\/09537104.2020.1869711","journal-title":"Platelets"},{"key":"2867_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.V75.5.1081.1081","volume":"75","author":"M Cattaneo","year":"1990","unstructured":"Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF (1990) Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 75:1081\u20131086. https:\/\/doi.org\/10.1182\/blood.V75.5.1081.1081","journal-title":"Blood"},{"key":"2867_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1017\/cts.2019.382","volume":"3","author":"S Vootukuri","year":"2019","unstructured":"Vootukuri S, Li J, NedBabayeva M, Coller BS (2019) Preclinical studies of RUC-4, a novel platelet alpha-2b beta 3 antagonist, in non-human primates and with human platelets. J Clin Transl Sci 3:65\u201374. https:\/\/doi.org\/10.1017\/cts.2019.382","journal-title":"J Clin Transl Sci"},{"key":"2867_CR30","unstructured":"White MM, Jennings LK (1999) Platelet protocols: Research and Clinical Laboratory Procedures. Academic Press, Inc."},{"issue":"1","key":"2867_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1540-8183.2002.tb01034.x","volume":"15","author":"LK Jennings","year":"2002","unstructured":"Jennings LK, Jacoski MV, White MM (2002) The pharmacodynamics of parenteral glycoprotein IIb-IIIa inhibitors. J Intervent Cardiol 15(1):45\u201360. https:\/\/doi.org\/10.1111\/j.1540-8183.2002.tb01034.x","journal-title":"J Intervent Cardiol"},{"key":"2867_CR32","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1055\/s-0041-1732343","volume":"5","author":"OS Bentur","year":"2021","unstructured":"Bentur OS, Li J, Jiang CS, Martin LH, Kereiakes DJ, Coller BS (2021) Application of auxillary VerifyNow point-of-care assays to assess the pharmacodynamics of RUC-4, a novel aIIbb3 receptor antagonist. TH Open 5:e449\u2013e460. https:\/\/doi.org\/10.1055\/s-0041-1732343","journal-title":"TH Open"},{"issue":"3","key":"2867_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/rth2.12107","volume":"2","author":"F Swieringa","year":"2018","unstructured":"Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ (2018) Integrating platelet and coagulation activation in fibrin clot formation. Res Pract Thromb Haemost 2(3):450\u2013460. https:\/\/doi.org\/10.1002\/rth2.12107","journal-title":"Res Pract Thromb Haemost"},{"key":"2867_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12959-015-0061-1","volume":"13","author":"CH Hansen","year":"2015","unstructured":"Hansen CH, Ritschel V, Halvorsen S, Anderson GO, Bjonerheim R, Eritsland J, Arnesen H (2015) Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction. Thromb J 13:31. https:\/\/doi.org\/10.1186\/s12959-015-0061-1","journal-title":"Thromb J"},{"issue":"9665","key":"2867_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(09)60441-4","journal-title":"Lancet"},{"key":"2867_CR36","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1093\/eurheartj\/ehi620","volume":"26","author":"Admiral Investigators","year":"2005","unstructured":"Admiral Investigators (2005) Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eu Heart J 26:2520\u20132523. https:\/\/doi.org\/10.1093\/eurheartj\/ehi620","journal-title":"Eu Heart J"},{"key":"2867_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMoa013404","volume":"346","author":"GW Stone","year":"2002","unstructured":"Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ (2002) Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute myocardial infarction. N Engl J Med 346:957\u2013966. https:\/\/doi.org\/10.1056\/NEJMoa013404","journal-title":"N Engl J Med"},{"issue":"9638","key":"2867_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","volume":"372","author":"AW Van\u2019t Hof","year":"2008","unstructured":"Van\u2019t Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C (2008) Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372(9638):537\u2013546. https:\/\/doi.org\/10.1016\/S0140-6736(08)61235-0","journal-title":"Lancet"},{"key":"2867_CR39","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1161\/01.cir.95.7.1755","volume":"95","author":"HK Gold","year":"1997","unstructured":"Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC (1997) Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Circulation 95:1755\u20131759. https:\/\/doi.org\/10.1161\/01.cir.95.7.1755","journal-title":"Circulation"},{"key":"2867_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.amjcard.2014.12.030","volume":"115","author":"G DeLuca","year":"2015","unstructured":"DeLuca G, van \u2019t Hof AW, Gibson CM et al (2015) Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation). Am J Cardiol 115:711\u2013715. https:\/\/doi.org\/10.1016\/j.amjcard.2014.12.030","journal-title":"Am J Cardiol"},{"issue":"05","key":"2867_CR41","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4244\/eijv4i5a110","volume":"4","author":"AK Hassan","year":"2009","unstructured":"Hassan AK, Jukema JW, van der Laarse A et al (2009) Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention 4(05):662\u2013668. https:\/\/doi.org\/10.4244\/eijv4i5a110","journal-title":"EuroIntervention"},{"key":"2867_CR42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","volume":"372","author":"AW van\u2019t Hof","year":"2008","unstructured":"van\u2019t Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JE, Suryapranata H, van Houwelingen G, Ottervanger JP et al (2008) Prehospital initiation of tirofiban in patients with ST-myocardial infarction undergoing primary angioplasty (On-Time 2): a multicentre, double-blind, randomized controlled trial. Lancet 372:537\u2013546. https:\/\/doi.org\/10.1016\/S0140-6736(08)61235-0","journal-title":"Lancet"},{"issue":"1","key":"2867_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4021\/cr251w","volume":"4","author":"L Iannetta","year":"2013","unstructured":"Iannetta L, Puddu PE, Cuturello D, Saladini A, Pellicano M, Schiariti M (2013) Is there still a role for glycoprotein IIb\/IIIa antagonists in Acute Coronary Syndromes? Cardiol Res 4(1):1\u20137. https:\/\/doi.org\/10.4021\/cr251w","journal-title":"Cardiol Res"},{"key":"2867_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ahj.2022.12.015","volume":"258","author":"S Rikken","year":"2023","unstructured":"Rikken S, Selvarajah A, Hermanides RS, Coller BS, Gibson MC, Granger CB, Lapostolle F, Postma S, van de Wetering H, van Vliet R, Montalescot G, ten Berg J, van\u2019t Hof AW (2023) Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. Am Heart J 258:119\u2013128. https:\/\/doi.org\/10.1016\/j.ahj.2022.12.015","journal-title":"Am Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02867-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02867-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:04:18Z","timestamp":1696417458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02867-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02867-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"8 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}},{"value":"Dr. Curry is an employee of MLM Medical Labs. Drs. Gibson, Grainger, van \u2018t Hof, ten Berg and Jennings serve as consultants of Celecor. Dr. Jennings has financial interests in MLM Medical Labs. This study was supported in part by Celecor Therapeutics, Del Mar, CA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}